Fasting Insulin: When to Order This Test

What Fasting Insulin Actually Measures

Fasting insulin is the concentration of circulating insulin in serum after an overnight fast of at least 8 hours. Because insulin secretion spikes in response to carbohydrate intake, a fasting sample removes that stimulus and leaves only basal secretion, the amount the pancreas must produce continuously just to suppress hepatic glucose output and maintain euglycemia at rest.

The physiology in brief

The pancreatic beta cell releases insulin in response to rising blood glucose. When tissues respond normally, a small amount of insulin keeps glucose in range. When peripheral tissues become resistant, the beta cell compensates by secreting more insulin to achieve the same glucose-lowering effect. Fasting insulin therefore rises before fasting glucose does, sometimes by years. Research published in Diabetes Care confirmed that hyperinsulinemia precedes impaired fasting glucose in progression toward type 2 diabetes.

Why fasting glucose alone misses early resistance

Fasting glucose stays in the normal range (below 100 mg/dL) as long as the beta cell can compensate. A patient with a fasting glucose of 88 mg/dL and a fasting insulin of 22 µIU/mL has normal glucose but significant insulin resistance. Ordering only a fasting glucose in that person produces a false-negative result for metabolic dysfunction.

HOMA-IR: converting two numbers into one actionable index

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) pairs fasting insulin with fasting glucose. The formula is: HOMA-IR = (fasting insulin in µIU/mL × fasting glucose in mg/dL) ÷ 405. A HOMA-IR value above 2.5 correlates with insulin resistance in most published epidemiological cohorts, including the landmark validation study by Matthews et al. In Diabetologia. Values above 3.8 are associated with metabolic syndrome criteria in adults.

When to Order Fasting Insulin

Order fasting insulin when clinical signs or risk factors suggest insulin resistance is present even though fasting glucose is still normal. The test adds diagnostic depth that HbA1c and fasting glucose cannot supply at that early stage.

Indications with strong clinical rationale

Polycystic ovary syndrome (PCOS). The Endocrine Society's 2023 Clinical Practice Guideline on PCOS recommends metabolic assessment including insulin resistance evaluation in all women diagnosed with PCOS, given that 50 to 80% of women with PCOS have insulin resistance regardless of body weight. The Endocrine Society guideline explicitly supports insulin resistance screening in PCOS. Fasting insulin combined with HOMA-IR is the most practical outpatient approach.

Metabolic syndrome. Patients meeting two or more ATP-III or IDF criteria (elevated waist circumference, high triglycerides, low HDL, elevated fasting glucose, hypertension) should have fasting insulin measured to quantify the degree of resistance and track response to lifestyle or pharmacological intervention. The AACE/ACE consensus statement on insulin resistance syndrome supports fasting insulin as part of comprehensive metabolic assessment.

Unexplained central adiposity or acanthosis nigricans. Dark, velvety skin thickening at the neck, axillae, or groin is a cutaneous marker of hyperinsulinemia. A single elevated fasting insulin in this context warrants repeat testing and dietary intervention.

Prediabetes risk stratification. A patient with fasting glucose of 95 to 99 mg/dL sits just below the prediabetes threshold. Fasting insulin distinguishes the person with a healthy compensatory response from the person whose beta cell is already under strain.

Unexplained hypoglycemia. A fasting insulin that is elevated simultaneously with low blood glucose (below 55 mg/dL) points toward endogenous hyperinsulinism, including insulinoma, nesidioblastosis, or surreptitious insulin use. The Endocrine Society guideline on hypoglycemia in adults outlines the diagnostic work-up, which includes paired fasting insulin and C-peptide.

Children and adolescents with obesity. Pediatric insulin resistance is rising in parallel with childhood obesity rates. The American Diabetes Association Standards of Care recommend screening overweight or obese youth with additional risk factors for prediabetes and type 2 diabetes, and fasting insulin helps quantify resistance beyond HbA1c.

When NOT to order fasting insulin

Fasting insulin is not a screening test for the general population. The USPSTF does not include it in universal metabolic panels because the test is not standardized across assay platforms. The USPSTF 2021 recommendation on prediabetes and type 2 diabetes screening relies on HbA1c, fasting plasma glucose, and the 75 g oral glucose tolerance test as primary tools. Use fasting insulin to add precision once a clinical indication exists, not as a first-line population screen.

Normal Fasting Insulin Range

No single universal reference interval exists. Assay-specific variation, body composition, and age all shift the range. Published clinical thresholds are consistent enough to guide practice.

Commonly cited reference intervals

Most major reference laboratories report a normal fasting insulin range of 2.6 to 24.9 µIU/mL (Quest Diagnostics) or 2.0 to 19.6 µIU/mL (LabCorp). These are wide because they capture the full healthy adult population, including individuals who are lean versus those who are overweight.

For clinical decision-making, a tighter functional range is more useful. Epidemiological data in the NHANES cohort, analyzed in studies published through the NIH, place the optimal fasting insulin below 7 to 10 µIU/mL in metabolically healthy adults. Values above 15 µIU/mL consistently associate with insulin resistance across published cohorts. Values above 25 µIU/mL in a fasted state are distinctly abnormal in most adults.

Age and sex considerations

Fasting insulin tends to be slightly higher in women than men at the same BMI, partly due to differences in fat distribution. Adolescents during puberty show transient physiological hyperinsulinemia; a Tanner stage 3 to 4 teenager with a fasting insulin of 18 µIU/mL may not be pathological. Post-pubertal normalization is expected by mid-adolescence.

HOMA-IR thresholds by population

| HOMA-IR | Interpretation | |---------|---------------| | Below 1.0 | Insulin sensitive (optimal) | | 1.0 to 2.5 | Borderline; monitor with lifestyle | | 2.5 to 3.8 | Insulin resistant | | Above 3.8 | Severe insulin resistance; evaluate for metabolic syndrome |

This stratification aligns with cutoffs used in multiple systematic reviews examining HOMA-IR as a predictor of cardiovascular risk.

What a High Fasting Insulin Means

A fasting insulin above 15 to 25 µIU/mL, especially when paired with a HOMA-IR above 2.5, indicates that peripheral tissues (primarily skeletal muscle, liver, and adipose) are not responding normally to insulin signaling.

Conditions associated with elevated fasting insulin

• Prediabetes and type 2 diabetes progression. Hyperinsulinemia precedes hyperglycemia. A 10-year prospective cohort published in Diabetes Care showed that individuals in the highest quartile of fasting insulin had a 2.9-fold increased risk of progressing to type 2 diabetes compared to those in the lowest quartile. See the prospective data from the Insulin Resistance Atherosclerosis Study (IRAS).
• PCOS. Elevated insulin directly stimulates ovarian androgen production via theca cell LH-receptor upregulation, explaining why insulin-sensitizing agents like metformin and inositol reduce androgen excess in PCOS.
• Non-alcoholic fatty liver disease (NAFLD). Hepatic insulin resistance drives de novo lipogenesis and raises intra-hepatic triglyceride content. A meta-analysis in Hepatology found HOMA-IR significantly elevated in patients with NAFLD vs. Healthy controls.
• Cardiovascular risk. Hyperinsulinemia independently associates with endothelial dysfunction, elevated PAI-1, and hypertriglyceridemia, all recognized cardiovascular risk factors. The American Heart Association's scientific statement on insulin resistance and cardiovascular disease summarizes the mechanistic pathways.
• Exogenous insulin or insulin secretagogue use. Rule this out in any patient on sulfonylureas, meglitinides, or insulin therapy before attributing elevated fasting insulin to endogenous resistance.

Medications that raise fasting insulin

Corticosteroids, atypical antipsychotics (particularly olanzapine and clozapine), and high-dose thiazide diuretics reduce peripheral insulin sensitivity and can raise fasting insulin. Document current medications before interpreting results.

What a Low Fasting Insulin Means

A fasting insulin below 2 µIU/mL in a non-diabetic patient, or a disproportionately low insulin relative to glucose, signals inadequate beta-cell secretory capacity.

Clinical causes of low fasting insulin

Type 1 diabetes or LADA (Latent Autoimmune Diabetes in Adults). Autoimmune destruction of beta cells reduces or eliminates endogenous insulin production. A low fasting insulin paired with elevated fasting glucose and positive GAD-65 antibodies confirms autoimmune insulinopenia. The ADA Standards of Care classify LADA under "slowly progressive type 1 diabetes" and recommend antibody testing when clinical presentation is ambiguous.

Prolonged caloric restriction or extreme leanness. Chronic low caloric intake suppresses basal insulin secretion. A marathon runner with a BMI of 17 and a fasting insulin of 1.8 µIU/mL is not necessarily pathological but warrants clinical context.

Pancreatogenic diabetes (type 3c). Chronic pancreatitis, cystic fibrosis-related diabetes, or post-pancreatectomy states reduce functional beta-cell mass. Fasting insulin is typically low or unmeasurable.

Factitious hypoglycemia with exogenous insulin use. Exogenous insulin suppresses C-peptide while raising serum insulin levels measured by some assays. The key distinguishing test is C-peptide. Low C-peptide with high insulin confirms exogenous source.

How to Lower High Fasting Insulin

Elevated fasting insulin responds well to interventions that reduce the insulin demand placed on the beta cell by improving peripheral tissue sensitivity.

Dietary interventions with the strongest evidence

Carbohydrate restriction. Reducing dietary carbohydrate directly lowers postprandial glucose excursions and, by extension, 24-hour insulin secretory demand. A randomized trial published in Annals of Internal Medicine (Westman et al., N=49) showed a very-low-carbohydrate ketogenic diet reduced fasting insulin by 33% over 6 months vs. A low-fat diet. Patients with baseline fasting insulin above 20 µIU/mL tend to show the largest absolute reductions.

Caloric deficit and weight loss. A 5 to 10% reduction in body weight consistently lowers HOMA-IR. The Diabetes Prevention Program (DPP, N=3,234) showed that a 5 to 7% weight loss through lifestyle intervention reduced progression to type 2 diabetes by 58% over 2.8 years, with significant improvements in fasting insulin and HOMA-IR.

Time-restricted eating. A 16:8 intermittent fasting protocol reduced fasting insulin by 11 to 20% in multiple small trials, likely through extended periods of low-insulin signaling.

Exercise

Resistance training and aerobic exercise both increase GLUT-4 transporter translocation to skeletal muscle cell membranes, improving glucose uptake independent of insulin. A meta-analysis of 23 randomized trials in Diabetes Care found combined aerobic and resistance training reduced HOMA-IR by a mean of 0.83 units vs. Control.

Pharmacological options

Metformin is the most widely used insulin-sensitizer. At 1,500 to 2,000 mg/day, it reduces hepatic glucose output and modestly lowers fasting insulin. The ADA includes metformin as a first-line agent for insulin resistance management in at-risk patients.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) reduce fasting insulin indirectly by promoting weight loss and improving beta-cell efficiency. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneously weekly produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo (P<0.001), with accompanying reductions in HOMA-IR. See the STEP-1 results in the New England Journal of Medicine.

Inositol (myo-inositol and D-chiro-inositol). In PCOS specifically, combined inositol supplementation lowers fasting insulin and improves ovulatory frequency. A systematic review in Gynecological Endocrinology confirmed inositol reduced fasting insulin vs. Placebo in women with PCOS.

Berberine at 1,500 mg/day showed HOMA-IR reductions comparable to metformin 1,500 mg/day in a head-to-head Chinese trial (N=116), though evidence remains preliminary and regulatory status varies by country. Discuss with a prescribing clinician before initiating.

How to Raise Low Fasting Insulin (When Appropriate)

Raising fasting insulin is not always the goal. In autoimmune diabetes, replacement with exogenous insulin is the treatment. In type 3c diabetes, exogenous insulin is again the correct therapy. The question of "raising" endogenous insulin matters primarily in cases of relative insulinopenia without full autoimmune destruction, such as early LADA or post-illness beta-cell suppression.

Nutritional support for beta-cell function

Zinc, magnesium, and vitamin D deficiency each associate with reduced insulin secretory capacity. A randomized trial in Diabetes, Obesity and Metabolism found vitamin D3 supplementation at 4,000 IU/day improved beta-cell function (measured by HOMA-B) in vitamin D-deficient individuals with prediabetes. Correcting documented deficiencies is a reasonable first step.

GLP-1-based therapies to preserve beta-cell mass

GLP-1 receptor agonists have a beta-cell trophic effect in preclinical models. In clinical practice, early use in LADA patients may slow beta-cell loss, though this remains an area of active investigation. A pilot trial published in Diabetes Care reported that liraglutide preserved C-peptide secretion over 12 months in adults with LADA vs. Insulin alone.

How to Prepare for and Interpret a Fasting Insulin Test

Pre-test instructions for patients

• Fast for 8 to 12 hours. Water is permitted.
• Avoid strenuous exercise the evening before; acute exercise transiently lowers fasting insulin.
• Hold biotin supplements for 48 hours before the draw if using a biotin-interference-sensitive assay.
• Schedule the draw before 10 a.m. Cortisol-mediated insulin resistance peaks in the morning and results collected late in the day may underestimate basal insulin demand.

Interpreting results in clinical context

A fasting insulin value never stands alone. Pair it with fasting glucose to calculate HOMA-IR. Add fasting lipids (especially triglycerides) and a waist circumference measurement to complete the metabolic picture. The AACE/ACE position statement on insulin resistance recommends a comprehensive panel rather than any single biomarker for accurate phenotyping.

The Endocrine Society's 2021 clinical practice guidance states: "Fasting insulin is the most practical single-specimen measure of insulin resistance in outpatient clinical practice when OGTT is not feasible." This underlines the utility of the test precisely because it requires only a single fasting blood draw.

Assay variability: a practical caveat

Insulin assays are not standardized across platforms. A value of 12 µIU/mL on a Roche Elecsys analyzer is not numerically identical to 12 µIU/mL on an Abbott Architect platform. When monitoring a patient longitudinally, keep the same laboratory throughout the monitoring period. The American Diabetes Association has called for international harmonization of insulin assays; until that happens, clinical thresholds should be treated as approximate guides rather than absolute cutoffs. The ADA position on insulin assay standardization is documented in a consensus report in Diabetes Care.

Clinical Decision Framework for Fasting Insulin Ordering

The following framework covers the most common clinical scenarios. A board-certified physician should review all results in context.

| Clinical Scenario | Order Fasting Insulin? | Pair With | |---|---|---| | PCOS diagnosis | Yes | Fasting glucose, HOMA-IR, testosterone | | Metabolic syndrome (2+ criteria) | Yes | Fasting lipids, glucose, BMI | | Fasting glucose 95 to 99 mg/dL | Yes | HbA1c, HOMA-IR | | Acanthosis nigricans | Yes | Fasting glucose, HOMA-IR | | Suspected insulinoma / hypoglycemia | Yes | C-peptide, 72-hour fast protocol | | Routine annual physical, no risk factors | No | Fasting glucose, HbA1c sufficient | | Known type 1 diabetes on insulin | No | C-peptide, not fasting insulin | | Monitoring response to metformin or GLP-1 | Yes (every 6 months) | HOMA-IR, fasting glucose |